Interactions of Kidney Function Related Genes and Proteins With Anticancer Drugs and Strategies To Mitigate Their Adverse Effects
ISEF · 2025 Cellular and Molecular Biology
Overview
Sorafenib, a targeted anticancer therapy, is used in the treatment of advanced renal cell carcinoma by inhibiting vascular endothelial growth factor receptors (VEGFRs) and tyrosine kinases (TKs), both essential for tumor growth. However, the use of sorafenib leads to adverse effects such as renal damage, particularly focal segmental glomerulosclerosis (FSGS). Currently, there are no effective therapeutics to mitigate sorafenib-induced renal damage, posing a significant clinical challenge. Epoxyeicosatrienoic acids (EETs) are being investigated for their renoprotective effects and represent a potential protective agent. However, they quickly degrade to the less active 8,9-DHET. This study investigates a novel, more bioavailable mimic, the 8,9-EET analog, specifically designed to reduce sorafenib-induced toxicities by modulating key gene expression pathways. Gene expression profiles were obtained from the Nephroseq database, with key gene targets analyzed via ingenuity pathway analysis. Cultured mesangial and tubular cells were treated with various combinations of sorafenib and the 8,9-EET analog to identify drug-enriched pathways. Results indicated that sorafenib-induced FSGS was linked to the downregulation of genes involved in cellular metabolism (CYP27B1, PDK4), transcription (ANKRD7, ZNF189), cytoskeletal integrity (ACTA2), and stress regulation (DUSP1). Conversely, pro-inflammatory and immune markers (IL10RA, PYCARD, TNFRSF-a, CX3CR1, ZFP36, TRIM32) were significantly upregulated, suggesting metabolic dysfunction, inflammation, and structural injury in renal tissues. Treatment with the 8,9-EET analog effectively balanced the expression of key renal genes, preserving renal function and enhancing the efficiency of VEGF-TKI therapies like sorafenib.
Competition history
- ISEF 2025
Resources
Related projects
ISEF · 2016
The Role of NF-E2 in Regulating Chemotherapeutic Metabolite Acrolein-Induced Nephrotoxicity
ISEF · 2016
Analysis of Different Nrf2 Inducers on Reversal of Stress-induced Changes in Renal Tubule Cells
ISEF · 2017
Potent Treatment of Renal Fibrosis: A Novel Inhibitor of HIPK2-Smad3 Interaction
ISEF · 2024
Metabolomics Unveils Novel Biomarkers for Early Diagnosis of Kidney Failure: Exploring the Therapeutic Effect of Naringenin and Cymbopogon proximus Essential Oil Combination
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair